Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tsumura & Co. (4540.T)
JPY3,855.00
-34.00 (-0.87%)
JP JPX Healthcare Drug Manufacturers - Specialty & Generic
Address
2-17-11, Akasaka 107-8521
Tokyo, JP
Tokyo, JP
CEO
Terukazu Kato
Website
tsumura.co.jp
IPO
2001-01-01
ISIN JP3535800001
Also trades on
Other OTC · TSMRF (USD)
Tokyo Stock Exchange · 4540.T (JPY)
Description
Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus on Kampo extract intermediates and granular Kampo preparations. Its operations are comprehensive, encompassing the full supply chain: from the careful acquisition, selection, processing, and warehousing of raw herbal materials and crude drug components for decoctions, to the manufacturing of powdered Kampo extracts and traditional Chinese medicines. Additionally, Tsumura & Co. is engaged in the sale of both pharmaceutical goods and food products.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY3,855.00
-34.00 (-0.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
295.9K
Beta
0.06
Float Shares
63.63M
Free Float %
85.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.39% | +4.19% | +0.88% | -6.57% | -3.20% | -8.29% | +7.05% | +37.56% | +8.24% | +56.45% | +1,100.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3,855.00
DCF (Unlevered)
3,077.00
-20.2%
DCF (Levered)
3,378.16
-12.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
25% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.44
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.4% Q1'26: +7.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-11.9% Q1'26: -13.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.4% Q1'26: +26.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.3% ★ Q1'26: +13.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.1% Q1'26: +4.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.6% ★ Q1'26: -1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.80× Q1'26: 3.36× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 2 Rev. Ana. 3 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
Mar 2029 3 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
110.44B
est: 111.43B (-0.9%)
|
112.63B
est: 114.10B (-1.3%)
|
114.95B
est: 115.53B (-0.5%)
|
117.88B
est: 119.47B (-1.3%)
|
120.91B
est: 120.20B (+0.6%)
|
123.25B
est: 125.23B (-1.6%)
|
130.88B
est: 131.50B (-0.5%)
|
129.55B
est: 128.61B (+0.7%)
|
140.04B
est: 139.00B (+0.8%)
|
150.85B
est: 157.50B (-4.2%)
|
181.09B
est: 183.53B (-1.3%)
|
195.04B
192.80B – 196.40B
+6.3% YoY
|
213.49B
207.46B – 216.80B
+9.5% YoY
|
224.24B
217.90B – 227.71B
+5.0% YoY
|
230.21B
229.08B – 231.34B
+2.7% YoY
|
238.55B
231.81B – 242.25B
+3.6% YoY
|
| EBITDA |
25.67B
est: 27.78B (-7.6%)
|
24.14B
est: 28.45B (-15.1%)
|
22.96B
est: 28.80B (-20.3%)
|
26.77B
est: 29.78B (-10.1%)
|
26.42B
est: 29.97B (-11.8%)
|
25.77B
est: 31.22B (-17.5%)
|
29.36B
est: 32.78B (-10.4%)
|
34.92B
est: 32.06B (+8.9%)
|
34.03B
est: 34.65B (-1.8%)
|
34.82B
est: 40.44B (-13.9%)
|
57.25B
est: 47.12B (+21.5%)
|
50.08B
49.50B – 50.43B
+6.3% YoY
|
54.82B
53.27B – 55.67B
+9.5% YoY
|
57.58B
55.95B – 58.47B
+5.0% YoY
|
59.11B
58.82B – 59.40B
+2.7% YoY
|
61.25B
59.52B – 62.20B
+3.6% YoY
|
| EBIT |
20.28B
est: 20.08B (+1.0%)
|
19.08B
est: 20.56B (-7.2%)
|
17.33B
est: 20.82B (-16.8%)
|
20.62B
est: 21.53B (-4.2%)
|
20.06B
est: 21.66B (-7.4%)
|
19.36B
est: 22.57B (-14.2%)
|
20.74B
est: 23.70B (-12.5%)
|
25.74B
est: 23.18B (+11.0%)
|
23.42B
est: 25.05B (-6.5%)
|
24.07B
est: 29.56B (-18.6%)
|
46.08B
est: 34.44B (+33.8%)
|
36.60B
36.18B – 36.86B
+6.3% YoY
|
40.06B
38.93B – 40.68B
+9.5% YoY
|
42.08B
40.89B – 42.73B
+5.0% YoY
|
43.20B
42.99B – 43.41B
+2.7% YoY
|
44.77B
43.50B – 45.46B
+3.6% YoY
|
| Net Income |
14.08B
est: 13.29B (+5.9%)
|
12.56B
est: 14.21B (-11.6%)
|
12.49B
est: 13.15B (-5.0%)
|
14.50B
est: 13.87B (+4.6%)
|
14.59B
est: 12.93B (+12.8%)
|
13.77B
est: 14.07B (-2.1%)
|
15.33B
est: 15.00B (+2.2%)
|
18.84B
est: 18.13B (+3.9%)
|
16.48B
est: 18.51B (-10.9%)
|
16.71B
est: 23.56B (-29.1%)
|
32.43B
est: 32.15B (+0.9%)
|
26.42B
25.54B – 28.01B
-17.8% YoY
|
26.95B
22.31B – 31.19B
+2.0% YoY
|
27.41B
20.57B – 33.08B
+1.7% YoY
|
25.10B
19.45B – 31.67B
-8.4% YoY
|
25.92B
24.97B – 26.45B
+3.3% YoY
|
| SGA |
42.84B
est: 33.18B (+29.1%)
|
41.78B
est: 33.97B (+23.0%)
|
43.43B
est: 34.40B (+26.2%)
|
45.18B
est: 35.57B (+27.0%)
|
47.01B
est: 35.79B (+31.3%)
|
47.35B
est: 37.29B (+27.0%)
|
48.92B
est: 39.15B (+24.9%)
|
36.78B
est: 38.30B (-4.0%)
|
39.77B
est: 41.39B (-3.9%)
|
40.51B
est: 45.44B (-10.9%)
|
42.10B
est: 52.96B (-20.5%)
|
56.28B
55.63B – 56.67B
+6.3% YoY
|
61.60B
59.86B – 62.55B
+9.5% YoY
|
64.70B
62.87B – 65.70B
+5.0% YoY
|
66.42B
66.10B – 66.75B
+2.7% YoY
|
68.83B
66.89B – 69.90B
+3.6% YoY
|
| EPS |
199.58
est: 175.08 (+14.0%)
|
178.05
est: 187.17 (-4.9%)
|
179.45
est: 173.22 (+3.6%)
|
200.54
est: 182.73 (+9.7%)
|
190.87
est: 170.38 (+12.0%)
|
179.96
est: 185.27 (-2.9%)
|
200.40
est: 197.62 (+1.4%)
|
246.20
est: 238.80 (+3.1%)
|
215.63
est: 248.34 (-13.2%)
|
219.82
est: 310.17 (-29.1%)
|
427.15
est: 427.03 (+0.0%)
|
352.05
336.40 – 368.88
-17.6% YoY
|
356.89
293.80 – 410.77
+1.4% YoY
|
365.65
271.00 – 435.79
+2.5% YoY
|
336.65
256.20 – 417.10
-7.9% YoY
|
341.45
328.91 – 348.33
+1.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.19B
OE per share TTM
-137.24
Owner's Yield
-3.87%
Maintenance CapEx ratio
82.98%
Maint CapEx / Avg PPE
66.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 101 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | UBS S&P Dividend Aristocrats ESG Elite UCITS ETF USD dis UBUM.DE | 0.69% | 1.43M | 0.30% |
| 2 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.26% | 990.7K | 0.58% |
| 3 | Dimensional - International Small Cap Value ETF DISV | 0.13% | 5.94M | 0.42% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.11% | 277.4K | 0.50% |
| 5 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.10% | 571.2K | 0.58% |
| 6 | WisdomTree International SmallCap Dividend Fund DLS | 0.09% | 945.3K | 0.58% |
| 7 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.09% | 387.4K | 0.48% |
| 8 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.08% | 533.0K | 0.41% |
| 9 | Dimensional - International Small Cap ETF DFIS | 0.06% | 3.72M | 0.39% |
| 10 | Schwab Fundamental International Small Company Index ETF FNDC | 0.06% | 1.78M | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
8.51M
Shares Outstanding
74.54M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Terukazu Kato | President, Chief Executive Officer & Chairman | 119M | male |
| Kaoru Kobayashi | Chief Financial Officer & Head of the Corporate Management Division | — | — |
| Kei Sugii | COO & Director | — | male |
| Koin Toda | Co-Chief Operating Officer | — | male |
| Koji Endo | Head of Human Resources Division, & Chief Human Resources Officer | — | — |
| Kouji Shiseki | Executive Officer & Head of Corporate Secretary Division | — | — |
| Makoto Kitamura | Head of Corporate Communications Dept. | — | — |
| Shoichi Kumagai | GM of Production Division & Executive Officer | — | — |
| Toshio Yamaoka | Executive Officer and Head of Pharmaceutical Sales & Marketing Division | — | — |
| Yoshiharu Watanabe | Executive Officer & Chinese Herbal Medicine Platform Director | — | — |
| Akihito Konda | Chief Technology Officer and Head of Research & Development Division | — | — |
| Zhang Lixian | Executive Officer & China Production Manager and China Pharmaceutical Platform Manager | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4540.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
